TENX — Tenax Therapeutics Share News
0.000.00%
Last trade - 00:00Brief: Tenax Therapeutics Files Prospectus Related To Resale Of Up To 21.2 Million Shares Of Common Stock By Certain Selling Stockholders - SEC Filing
Brief: Tenax Announces Successful Comparative Pharmacokinetic Study Of Pulmonary Arterial Hypertension Treatment
Brief: Tenax Therapeutics Announces $8 Million PIPE Offering Priced At-the-Market under Nasdaq Rules
Brief: Tenax Sees Cash, Cash Equivalents, Marketable Securities To Be Enough To Fund Ops Through Q2
Tenax Therapeutics Inc expected to post a loss of 16 cents a share - Earnings Preview
Brief: Tenax Therapeutics Enters Into Amendment To License Agreement Of Co, Orion Corp Dated As Of September 20, 2013
Brief: Tenax Therapeutics Granted U.S. Patent For The Subcutaneous Use Of Levosimendan
Brief: Tenax Therapeutics Provides Update On Tnx-102, Tnx-103 And Tnx-201 Clinical Programs
Tenax Therapeutics Inc reports results for the quarter ended in September - Earnings Summary
Brief: Tenax Therapeutics Says Expects Phase 3 Trial Of PAH To Begin In Q2 Of 2022
Tenax Therapeutics Inc expected to post a loss of 13 cents a share - Earnings Preview
Brief: Tenax Therapeutics CFO Michael Jebsen To Separate From Co
Tenax Therapeutics gains after FDA clears hypertension drug application
Brief: Tenax Therapeutics Announces Clearance Of The Investigational New Drug Application For Imatinib In Pulmonary Arterial Hypertension
Brief: Tenax Therapeutics Files Prospectus Relates To Resale Of Up To 9.5 Mln Shares Of Common Stock
Brief: Tenax Therapeutics Inc Says On July 7, Christopher T. Giordano Was Appointed CEO, Director, Effective July 14
Tenax Therapeutics Inc reports results for the quarter ended in June - Earnings Summary
Tenax Therapeutics Inc expected to post a loss of 13 cents a share - Earnings Preview
Brief: Tenax Announces New Publication Highlighting Novel Levosimendan Mechanism Of Action In Pulmonary Hypertension Patients With Heart Failure And Preserved Ejection Fraction (Ph-Hfpef)